Multispecific Antibody Production Services

Creative Biolabs is dedicated to providing integrated multispecific antibody production services to our valued customers. In addition to our standard services, we also offer custom multispecific antibody development services to meet the specific needs of our customers.

Platform

Currently, the research and development of multispecific antibodies is considered a prominent area of focus. Multispecific antibodies have a broader application potential, as they can simultaneously bind to multiple antigens, resulting in a more potent therapeutic effect.

Our extensive expertise in the development of multispecific antibodies allows clients to tailor and manufacture a variety of multispecific antibody formats. Utilizing either a hybridoma cell line or an existing antibody sequence, we offer customized production of multispecific antibodies ranging from milligrams to grams.

The innovative multispecific antibodies generated by Creative Biolabs have opened up new avenues for therapeutic intervention that go beyond the capabilities of traditional monoclonal antibodies. These antibodies facilitate the localized delivery of drugs to tumors, enhance binding specificity, optimize drug targeting of tumor cells, and minimize off-target toxicity.

Fig.1 All Multispecific Antibody Formats.^1,3

Services

According to the mechanism of action of multispecific antibodies, Creative Biolabs has mainly divided multispecific antibody production services into the following three categories:

• Multi-specific antibody production solutions based on bridging cells

We use different bridging immune cells and tumor cells, such as T cells and tumor cells, one end of the antibody binds to the surface molecule of the T cell and the other end binds to the surface molecule of the tumor cell so that the T cell can activate the T cell to attack the tumor cell nearby. For example, we will use different immune cell surface molecules, such as EpCAM, CD19, CD40, 4-1BB, CD16, and surface molecules that are abundant in tumor cells, such as CD3, CD20, CD33, CD38, HER2, PSMA, mesothelin, MET, PD-L1 are the main targets for development, and multi-specific antibodies are designed and developed.

• Multispecific antibody production solutions based on bridging receptors/factors

Some ligands or cytokines induce activation of intracellular signaling pathways, such as VEGF, ANG2, DLL4, TNF, IL-23, and IL-17. They can be simultaneously inhibited by multispecific antibodies so that they cannot cause subsequent intracellular message transmission and cell function, and thus achieve therapeutic effect. In addition, we can also target the major receptors of tumor cells, such as HER2, EGFR, MET, etc., and inhibit the receptor so that it cannot activate downstream message transmission.

• Multispecific antibody production solutions based on multiple immune checkpoints

Our current development strategy is to design multi-specific antibodies by targeting multiple immune checkpoints simultaneously, either as antagonists or agonists, with one end targeting tumor cells and one end targeting checkpoints that enhance immune cell activation. For example, we designed a tri-specific antibody with one site targeting tumor cells (CD20) and two sites at the other end binding to both CD3 and CD28, thereby activating T cells to attack tumor cells.

Fig.2 The Role of CSF1R/CCR2/TGF-β Multispecific Ab Drugs on the Treatment of TAMs.^2,3

Procedures

1. Design: The design of a multispecific antibody typically involves combining two or more binding domains from different antibodies or designing de novo binding domains. In our labs, computational modeling and engineering techniques are employed to optimize the binding affinity and specificity of each domain for its target.
2. Production: The multispecific antibody is produced using recombinant DNA technology. The sequence encoding the engineered binding domains is cloned into expression vectors and transfected into mammalian or bacterial cells. The antibody is then purified using protein purification techniques such as chromatography.
3. Validation: Before the multispecific antibody can be used for therapeutic or diagnostic purposes, it must undergo rigorous validation to ensure its efficacy and safety. We will test the antibody for binding specificity, affinity, and functionality using both in vitro and in vivo assays. Furthermore, the antibody's stability, pharmacokinetics, and immunogenicity can also be evaluated.
4. Quality Control (QC) process: The QC process for multispecific antibodies involves a series of tests and analyses to ensure the antibody meets the necessary quality standards.

Fig.3 Our Multispecific Antibody Service Features. (Creative Biolabs Original)

Creative Biolabs has years of experience in multispecific antibody production and can deliver top-quality results for every project. Our commitment to excellence and customer satisfaction is unparalleled, and we are confident in our ability to meet and exceed your expectations. Please feel free to contact us with any inquiries or to place an order.

References

1. Elshiaty, Mariam, Hannah Schindler, and Petros Christopoulos. "Principles and current clinical landscape of multispecific antibodies against cancer." International journal of molecular sciences 22.11 (2021): 5632.
2. Nguyen, Huu Tuan, et al. "Patient-Specific Vascularized Tumor Model: Blocking TAM Recruitment with Multispecific Antibodies Targeting CCR2 and CSF-1R." Biomaterials (2024): 122731.
3. under Open Access License CC BY 4.0, without modification.

For research use only. Not intended for any clinical use.